{
    "response": "**Overall Treatment Decision:** Yes\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute inflammatory demyelinating event with functional deficits Improves speed of neurological recovery Low infection markers and no contraindications evident\n\n*   **Treatment:** Proton pump inhibitor and glucose monitoring during steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Gastroprotection with high-dose steroids Mitigate steroid-induced hyperglycaemia risk\n\n*   **Treatment:** Plasma exchange (5\u20137 sessions)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for steroid-refractory attack within 2 weeks Particularly indicated if MRI/serology suggests NMOSD or severe myelitis\n\n*   **Treatment:** Initiate disease-modifying therapy for MS (agent per phenotype and risk profile)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only after diagnostic confirmation (McDonald criteria) Choice depends on MRI burden, relapse severity, and serology (exclude AQP4/MOG)\n\n*   **Treatment:** Physiotherapy and occupational therapy\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Address gait unsteadiness and right-sided weakness Prevents deconditioning and promotes functional recovery\n\n*   **Treatment:** Venous thromboembolism prophylaxis if mobility reduced\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Immobility from myelitis increases VTE risk Safe alongside steroids\n\n*   **Treatment:** Vitamin D supplementation\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Common deficiency in demyelinating disease Potential relapse risk reduction and general bone health during steroids\n\n*   **Treatment:** Targeted symptomatic therapy (e.g., baclofen for spasticity, gabapentin for neuropathic pain)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Tailor to symptom burden after initial steroid response Avoid overtreatment if deficits rapidly improve\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute inflammatory demyelinating event with functional deficits\", \"Improves speed of neurological recovery\", \"Low infection markers and no contraindications evident\"]}, {\"treatment\": \"Proton pump inhibitor and glucose monitoring during steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Gastroprotection with high-dose steroids\", \"Mitigate steroid-induced hyperglycaemia risk\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 sessions)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for steroid-refractory attack within 2 weeks\", \"Particularly indicated if MRI/serology suggests NMOSD or severe myelitis\"]}, {\"treatment\": \"Initiate disease-modifying therapy for MS (agent per phenotype and risk profile)\", \"timing\": \"Delay\", \"reasons\": [\"Start only after diagnostic confirmation (McDonald criteria)\", \"Choice depends on MRI burden, relapse severity, and serology (exclude AQP4/MOG)\"]}, {\"treatment\": \"Physiotherapy and occupational therapy\", \"timing\": \"Start Now\", \"reasons\": [\"Address gait unsteadiness and right-sided weakness\", \"Prevents deconditioning and promotes functional recovery\"]}, {\"treatment\": \"Venous thromboembolism prophylaxis if mobility reduced\", \"timing\": \"Start Now\", \"reasons\": [\"Immobility from myelitis increases VTE risk\", \"Safe alongside steroids\"]}, {\"treatment\": \"Vitamin D supplementation\", \"timing\": \"Start Now\", \"reasons\": [\"Common deficiency in demyelinating disease\", \"Potential relapse risk reduction and general bone health during steroids\"]}, {\"treatment\": \"Targeted symptomatic therapy (e.g., baclofen for spasticity, gabapentin for neuropathic pain)\", \"timing\": \"Delay\", \"reasons\": [\"Tailor to symptom burden after initial steroid response\", \"Avoid overtreatment if deficits rapidly improve\"]}]"
}